ESR1 and breast cancer: However, whereas ER-, PR- or Her2-positive BC patients can now be managed with targeted therapies, triple-negative breast cancer (TNBC) tumors, i.e., those that do not express any of these three key factors, lack molecular markers for diagnosis and therapeutic targets 4 for treatment.